M2Gen's CEO Wants to Take Personalized Cancer Treatment to the Masses
Typically, such molecular and clinical patient information isn’t shared among cancer centers, hospitals and pharmaceutical companies, but M2Gen’s database — dubbed the Oncology Research Information Exchange Network (ORIEN) — is challenging that tradition. ORIEN gets data from 17 cancer centers across the country, including Moffitt. Pharmaceutical companies pay to subscribe to the network’s database.
Want to read the whole article?
Select from the following options:
* offer valid for new subscribers only